Inclusion Criteria
- Males or females ≥ 12 years of age
- Otherwise healthy and well controlled subjects
Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects
The objectives of this study are:
- To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced
mydriasis across multiple mydriatic agents with an emphasis on phenylephrine
- To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after
worsening (with cycloplegic agents tropicamide and Paremyd)
- To evaluate the safety of Nyxol
- To evaluate any additional benefits of the reversal of pharmacologically-induced
mydriasis
Phase 3
185
December 23, 2020
Interventional
Ocuphire Pharma, Inc.
The following cities have clinical trial sites that are either recruiting or will be soon.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
Contact a Trial Coordinator for more information on our trials.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
A Clinical Trial is a type of research study that examines how well a potential therapy works in humans.
The objectives of this study are:
This clinical trial has certain criteria that a person has to meet to determine if they can participate. Please discuss the trial with your doctor, and then please visit clinicaltrial.gov to find further contact information.
Ocuphire Pharma is sponsoring this clinical trial.
There will be a total of 168 patients enrolled in this clinical trial.